Plain-English translation of NCT06086197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a combination of four medications — including anlotinib, a drug that works differently from standard chemotherapy — can help treat a serious type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has either come back quickly after initial treatment or never responded to it in the first place. The researchers believe that adding anlotinib to standard chemotherapy drugs (rituximab, gemcitabine, and oxaliplatin) may work better than standard treatment alone. About 41 patients will receive this new combination to see if it improves their chances of recovery.
Many people with DLBCL either don't respond to their first treatment or see their cancer come back within a year—and these patients have a very poor outlook with current options. Researchers believe that by adding a medication that targets blood vessel growth to standard chemotherapy, they may be able to help patients whose lymphoma is resistant to conventional treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication combination as an outpatient over 6 treatment cycles, with each cycle lasting 21 days. During each cycle, you'll take anlotinib by mouth for 14 days and receive intravenous chemotherapy infusions (rituximab, gemcitabine, and oxaliplatin) on specific days. You'll have regular blood tests and imaging scans to monitor how well the treatment is working and to watch for side effects. The study will track your progress over time to see whether this new combination helps control your lymphoma better than standard treatments alone.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China